Shandong Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG, and what generic alternatives to SHANDONG drugs are available?
SHANDONG has ten approved drugs.
There are five US patents protecting SHANDONG drugs. There is one tentative approval on SHANDONG drugs.
There are twenty-seven patent family members on SHANDONG drugs in fourteen countries and twenty-one supplementary protection certificates in ten countries.
Summary for Shandong
| International Patents: | 27 |
| US Patents: | 5 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 10 |
Drugs and US Patents for Shandong
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 207375-003 | May 7, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-004 | Jan 13, 2023 | RX | Yes | Yes | 9,446,135 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-002 | Jan 13, 2023 | RX | Yes | Yes | 9,532,991 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Shandong | ISOSORBIDE MONONITRATE | isosorbide mononitrate | TABLET, EXTENDED RELEASE;ORAL | 214115-002 | Feb 8, 2024 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-001 | Jan 13, 2023 | RX | Yes | Yes | 11,110,094 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shandong Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20140026481 | ⤷ Try a Trial |
| Russian Federation | 2586306 | ⤷ Try a Trial |
| Spain | 2855349 | ⤷ Try a Trial |
| Hungary | E032310 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2012146052 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shandong Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0521471 | 03C0043 | France | ⤷ Try a Trial | PRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106 |
| 0740668 | PA2003001,C0740668 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
| 0720599 | 300688 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724 |
| 0740668 | 03C0017 | France | ⤷ Try a Trial | PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112 |
| 2101777 | CA 2016 00024 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
